TOP HEADLINES

Featured Story

'Magic bullet' nanoparticle treats lung trauma in intensive care

A new nanoparticle drug-delivery platform created by researchers at Queen's University Belfast may be able to target and effectively treat severe lung trauma in patients in intensive care.

New polymers shatter to release drugs at specific target

A new delivery platform called chain-shattering polymers developed by researchers at the University of Illinois could hold the key to the more controlled release of drugs at localized sites and tissues.

 

FDA accepts Merck's sublingual allergy med license application

Merck won the FDA's acceptance of a Biologics License Application for its investigational ragweed pollen allergy tablet to be delivered under the tongue.

Scripps study reveals new RNA-drug targeting potential

In another step toward realizing the elusive potential of RNA drugs, scientists at the Scripps Research Institute have nailed down one of the mechanisms by which the gene-silencers reach their targets in the cell's nucleus.

Frederick National Lab leads nanotech boom with cancer drug delivery

Researchers at the Frederick National Laboratory for Cancer Research have developed a way to enhance delivery of a cancer drug using nanoparticles, enabling more of the toxic therapy to reach the tumor without killing healthy cells.

MORE NEWS

From Our Sister Sites

FierceBiotech

The North Chicago, IL-based drug giant and Belgium's Galapagos have agreed to expand their collaboration on an oral JAK1 inhibitor to include Crohn's disease.

FiercePharma

A federal judge in Australia has put the kibosh on a half-million-dollar settlement over ill effects of Merck's ($MRK) painkiller Vioxx, a drug that has spawned billions of dollars in litigation.